Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06996782 · ClinicalTrials.gov registry record · Phase 1
A Platform Study in Non-Small Cell Lung Cancer (NSCLC)
A Phase 1 study of Advanced or Metastatic Non-Small-Cell Lung Cancer, sponsored by AstraZeneca.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 152
- Enrollment target
- 20
- Study locations
NCT06996782: Recruiting Phase 1 study of Advanced or Metastatic Non-Small-Cell Lung Cancer, sponsored by AstraZeneca.
NCT06996782 is a Phase 1 study of Advanced or Metastatic Non-Small-Cell Lung Cancer that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 152 participants, below the 427-participant average among 3 other Advanced or Metastatic Non-Small-Cell Lung Cancer trials with a reported enrollment target (64% lower). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06996782, a Phase 1 study of Advanced or Metastatic Non-Small-Cell Lung Cancer, is actively recruiting participants, sponsored by AstraZeneca.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 152 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to assess the safety and efficacy of multiple study interventions including novel-novel combinations or novel agents in combination with standard therapy for the treatment of metastatic NSCLC.
Primary Outcome
To assess the safety and tolerability and determine RP2D of the combination of novel anti-cancer agents.
Conditions Studied
Interventions
- DRUG Carboplatin
- DRUG Cisplatin
- DRUG Pemetrexed
- DRUG Paclitaxel
- DRUG Rilvegostomig
Study Locations (20)
Other
- Research Site - Anderlecht
- Research Site - Hasselt
- Research Site - Leuven
- Research Site - Barretos
- Research Site - Fortaleza
- Research Site - Natal
- Research Site - Pelotas
- Research Site - Porto Alegre
- Research Site - São Paulo
- Research Site - São Paulo
Rhode Island
- Research Site - Providence
- Research Site - Providence
Arizona
- Research Site - Phoenix
California
- Research Site - Santa Rosa
Florida
- Research Site - Jacksonville
Maryland
- Research Site - Baltimore
Michigan
- Research Site - Detroit
Minnesota
- Research Site - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 152 participants |
| Start Date | 2025-11-24 |
| Est. Completion | 2029-02-23 |
| Phase | Phase 1 |
What NCT06996782 shows while recruiting
NCT06996782 is an interventional study that assigns participants to a tested intervention. The registered 152 participants enrollment target is mid-sized for trials with a published cap, below the 427-participant average among 3 other Advanced or Metastatic Non-Small-Cell Lung Cancer trials with a reported enrollment target (64% lower).
The record links to 1 condition, with Advanced or Metastatic Non-Small-Cell Lung Cancer appearing as the primary indexed condition, and to 5 interventions - of which Carboplatin is the first listed.
NCT06996782 names 20 study sites across 10 states, led by Other, Rhode Island, Arizona.
Frequently Asked Questions
What is clinical trial NCT06996782 about?
NCT06996782 is a clinical study titled "A Platform Study in Non-Small Cell Lung Cancer (NSCLC)". The purpose of this study is to assess the safety and efficacy of multiple study interventions including novel-novel combinations or novel agents in combination with standard therapy for the treatment of metastatic NSCLC.
What is the current status of trial NCT06996782?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 152 participants. The study started on 2025-11-24. Estimated completion is 2029-02-23.
What conditions does trial NCT06996782 study?
This clinical trial studies the following conditions: Advanced or Metastatic Non-Small-Cell Lung Cancer.
What interventions are being tested in trial NCT06996782?
The interventions under investigation include: Carboplatin (DRUG), Cisplatin (DRUG), Pemetrexed (DRUG), Paclitaxel (DRUG), Rilvegostomig (DRUG).
Who is sponsoring clinical trial NCT06996782?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06996782 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Maryland, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced or Metastatic Non-Small-Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Novel Treatment Combinations in Patients With Lung Cancer
RECRUITING · Phase 2
-
A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer
ACTIVE NOT RECRUITING · Phase 3
-
A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03328078 · 152 participants · Phase 1
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
- NCT04458532 · 152 participants · NA
Exercise Therapy to Improve Cardiovascular Health in Post-Menopausal Women After Treatment for Early Stage Breast Cancer
- NCT04858334 · 152 participants · Phase 2
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
- NCT04993859 · 152 participants
Impact of Chemotherapy on Urinary Biomarkers and Non-Invasive Urodynamics in Children
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI